Bankinter| Laboratorios Almirall (ALM) has acquired the rights to distribute a product to treat Alzheimer’s disease in Spain. The agreement gives Almirall exclusive rights to a transdermal patch ...

Alexis Dunne always plans how to best treat her patients’ perimenopause and menopause symptoms. The Chicago-area physician wants to ensure that the hormone replacement therapy she prescribes helps ...

Transdermal estradiol (tE2) is an alternative to luteinizing hormone–releasing hormone (LHRH) agonists as androgen-deprivation therapy in patients with prostate cancer. With tE2, testosterone is ...

Regulatory authorities in China have cracked down on Sun Pharma’s rivastigmine-based Alzheimer’s disease treatment, halting the med’s distribution after uncovering shortfalls in its production process ...

Women who used transdermal hormone therapy (HT) to treat menopausal symptoms experienced lower rates of anxiety and depression than those who used oral HT, found a study presented at The Menopause ...

TOKYO, March 31, 2025 /PRNewswire/ -- Luye Pharma Group today announced that marketing approval for its innovative formulation Rivastigmine Twice Weekly Transdermal Patch has been granted by the ...

Which patients with metastatic hormone-sensitive prostate cancer (mHSPC) benefit more from androgen receptor pathway inhibitors (ARPIs)? STOPCAP meta-analyses of individual participant data (IPD).

Rivastigmine is a drug that may help people with Alzheimer’s disease improve thinking, memory, communication, and how they perform activities. It is a daily patch people wear on the skin. Alzheimer‘s ...

China’s National Medical Products Administration has approved Sino Biopharmaceutical Ltd.’s rivastigmine transdermal patch to treat mild to moderate Alzheimer’s disease. Developed by Sino Biopharm, ...